TET3 antibody selection and validation for a target nobody has benchmarked

Judging the reagent before you buy

1. Read the immunogen, not the marketing. Which region of the protein, and is it shared with the family? Enzymes and regulators frequently sit in families with high similarity, so an antibody raised against a conserved domain will recognise the relatives too. If the immunogen sequence is not disclosed, that itself is information.
2. Check the applications claimed against the evidence shown. A datasheet listing six applications with one western blot image has evidence for one. Treat each application as separate: performance on a denatured blot says very little about performance on a fixed section or in a pulldown.
3. Insist on a genetic negative where one is possible. A knockout or knockdown sample is the only control that distinguishes specific binding from a band of the right size. Where no knockout exists, an overexpression sample is the next best thing and considerably better than nothing.
4. Prefer a recombinant monoclonal for a long project. For a target you will work on for years, a defined sequence removes lot variation entirely. A polyclonal against a niche target may be a single bleed, and when it is gone the project restarts its validation from the beginning.
5. Buy one lot, and bank it. Ask the supplier how much of the lot remains before committing. For a low-demand target the answer is often small, and discovering that halfway through a study is the expensive version of this conversation.

Recording what you did, so the next person does not repeat it

Catalogue number, lot, dilution, application, sample, and the control that was run, kept with the result. For a niche target your own record becomes the literature, and a year later you will be the person asking whether this reagent was ever properly tested.

Publish the validation images as supplementary material where you can. Antibody validation that stays in a notebook is validation the field pays for again.

When no usable antibody exists

Epitope tagging the endogenous locus removes the problem entirely: a well characterised tag antibody works the same way on every target. It costs an editing project and it is frequently faster than screening six antibodies that do not work.

Where the readout can be transcript rather than protein, quantitative PCR or sequencing avoids the reagent problem altogether. It answers a different question, and it is worth being explicit about which question the experiment actually needs answered.

Buying from a smaller supplier

Niche targets are often served by smaller specialists, and the useful questions are whether the antibody is made in house or resold, what the lot history is, and whether they will supply a small trial size. A supplier who resells cannot answer questions about production.

Ask for a trial size before the full vial. Suppliers who believe in a reagent generally agree; the ones who refuse have told you something useful.

An olfm4 antibody and an intestinal stem cell marker

OLFM4 is secreted and marks intestinal crypt base cells in human tissue, so an olfm4 antibody reads a crypt pattern that is itself the control, and species differences are large enough that a human validated clone says little about mouse. Because the protein is secreted and glycosylated, the band is broad and lumenal staining is expected beside the cellular signal.

A trps1 antibody and a marker used to call a lineage

TRPS1 has become a breast lineage marker in pathology because it stays positive where the older markers are lost, so a trps1 antibody is scored as nuclear positivity with a stated cutoff rather than as an intensity. The clone and the retrieval it was validated with are part of that scoring. Expression in other tissues means the panel rather than this stain alone carries the inference.

A chmp4b antibody and the membrane scission machinery

CHMP4B is part of the complex that cuts membranes during division and repair, so a chmp4b antibody is read as recruitment to a site rather than as a level, and the informative experiment is imaging with a damage or division marker. The protein polymerises, so an insoluble fraction holds the assembled pool that a standard lysate leaves behind.

A wfs1 antibody and a marker of a cell population

WFS1 is an endoplasmic reticulum membrane protein used as a marker for particular neuronal and islet populations, so a wfs1 antibody is judged by that pattern and by a compartment marker beside it. It is multipass, which sets the sample preparation, and loss of function causes disease, so patient derived material is the negative control the literature uses when it can.

A ppat antibody and an enzyme at the start of a pathway

PPAT commits ribose to purine synthesis and is regulated allosterically rather than by abundance, so a ppat antibody measures expression and a labelled tracer measures flux. Expression differences between lines are the usual readout, which makes a stated loading reference the basis of the figure. The enzyme is part of a multienzyme assembly, which a native preparation can show.

A cblb antibody and an E3 ligase read through its targets

CBL-B ubiquitinates receptors to switch signalling off, so a cblb antibody reports the ligase while the readout is its substrate's level or ubiquitination. Its own abundance changes little. The family shares domains, so specificity against the related ligase is the line to read, and a knockout or knockdown lane is what makes a band attributable.

Common questions

How do I validate a CYP26B1 antibody, or any antibody nobody has published on?

With a genetic negative if one exists, an overexpression positive if it does not, a size check against the predicted mass with the modifications you expect, and a second antibody against a different epitope. Agreement between two independent antibodies is the strongest evidence available without a knockout.

Is a polyclonal or a recombinant monoclonal better for a niche target?

A polyclonal is often more sensitive and is finite. A recombinant monoclonal is reproducible indefinitely and can be reformatted. For a multi-year project the recombinant is usually the cheaper decision by the end.

What if a RAB27B antibody detects a band of the wrong size?

Check the predicted mass against known isoforms and modifications before concluding anything, then run the genetic control. A band at an unexpected size that disappears in a knockout is real biology; one that does not is the antibody.

Does a supplier's validation badge mean the antibody is validated?

It means the supplier applied its own scheme, and those schemes differ a great deal. Read what was actually done and in which application, and treat it as a starting point for your own control rather than as a substitute.

Browse by service class

• Compare Gene synthesis on advertised prices